S

Stryker

Manufactures orthopedic and surgical medical devices

Portfolio Manager - Knee

Full-Time
$107.2k - $178.6k/yr
Mid
Bachelor's, MBA
Mahwah, NJ, USA
HybridHybrid work; travel required 30%.
ProductProduct Management
Company Historically Provides H1B Sponsorship

About the job

Requirements
  • A bachelor's degree is required.
  • At least four years of work experience is required.
  • Excellent presentation and interpersonal communication skills.
Responsibilities
  • Develop portfolio and product strategies by translating customer, patient, and market insights into value propositions and growth opportunities.
  • Use qualitative and quantitative market research, Voice of Customer (VOC), competitive intelligence, and third-party data to identify customer needs, industry trends, and market opportunities.
  • Partner cross-functionally throughout the New Product Development (NPD) process to advance new products from concept through commercialization.
  • Build financial business cases and return on investment (ROI) models to evaluate new product opportunities and support investment decisions.
  • Develop market assessments, volume forecasts, and commercialization strategies based on market dynamics, customer insights, risk, and uncertainty.
  • Partner with Product Marketing to develop go-to-market and product launch strategies for new products.
  • Identify opportunities for customer acquisition, retention, market expansion, and portfolio growth, and evaluate associated financial tradeoffs.
  • Partner with Clinical Affairs and Product Marketing to develop clinical evidence, publication, and messaging strategies that support portfolio objectives.
  • Lead Product Lifecycle Management (PLCM) activities aligned with the broader portfolio and business strategy.
  • Develop pricing strategies aligned with market dynamics, customer value, brand positioning, and overall marketing strategy.
  • Support the development of sales enablement tools, marketing channels, and commercial communications that drive product adoption.
  • Build cross-functional partnerships across Marketing, R&D, Clinical Affairs, Finance, Sales, and other key functions to achieve portfolio objectives.
Desired Qualifications
  • An MBA is preferred.
  • At least two years of medical device or marketing experience is preferred.

About the company

Stryker makes medical devices for hospitals, surgical centers and emergency responders, spanning joint implants, surgical instruments and patient transport equipment. Its Mako platform assists surgeons with joint replacement, while its neurotechnology products support brain and spine procedures and stroke treatment. Clinicians use its equipment during surgery and emergency care, and the company earns money by selling implants, disposable products and capital equipment through direct sales teams and distributors. The business also supplies training and technical support for healthcare providers using its devices. Stryker was founded in 1941 and is headquartered in Portage, Michigan.

Company Size

10,001+

Company Stage

IPO

Headquarters

Portage, MI

Founded

1941

Get referred to Stryker

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Demand supports growth: July 2026 Stryker results show organic sales rose 9%, with reported sales reaching $6.6 billion.
  • Service extends equipment sales: Stryker's ProCare contracts bundle preventive maintenance, repairs and original manufacturer parts.
  • Relocation is available for Worcester technicians: Stryker's live transport service opening also lists 12 paid holidays.

What critics are saying

  • Operational failures reach customers: March 2026 cyberattack disrupted Stryker's ordering, manufacturing and shipping.
  • Older implants retain legal exposure: Stryker's recall estimates include Rejuvenate, LFIT V40 and legacy Wright hip products.
  • Field service demands travel: Stryker's northern Minnesota opening lists 80% travel plus evening or weekend call.

What makes Stryker unique

  • Mako combines imaging and physical guidance: Stryker uses CT-based planning and haptic boundaries during hip replacement.
  • Discarded devices return to service: Stryker's Sustainability Solutions reprocesses medical equipment for hospitals across the U.S. and Canada.
  • Transport extends its technology outside hospitals: Stryker's Power-LOAD supports stretchers while loading and unloading ambulances.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Medical & prescription plans
  • Supplemental health benefits
  • Flexible Spending accounts
  • Employee Assistance Program
  • Short-term & long-term disability
  • Tuition reimbursement
  • 401(k) plan
  • Employee Stock Purchase Plan

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Nov 1st, 2026
Stryker misses Q3 estimates with $6.52B revenue as orthopaedics slows and guidance is cut

Stryker missed Wall Street expectations in the third quarter of 2026, even as sales rose 7.6% year on year to $6.52 billion. Analysts had expected $6.62 billion. Adjusted earnings of $3.52 per share fell short of the $3.55 consensus. The medical technology company blamed a slowdown in US hip and knee replacements, citing patient affordability, more insurance pre-authorization denials, and problems after a new SAP system rollout. Operating margin fell to 15.9% from 18.7% a year earlier. Stryker cut its full-year adjusted earnings guidance to $14.85 per share at the midpoint, down 1.2%. It expects softness to continue, but is counting on product launches, robotics, and recent acquisitions, including ZuriMED, to drive growth. Shares trade at $296.17, down from $311.75 before the results.

Yahoo Finance
Oct 30th, 2026
Stryker shares fall 10% as 2026 sales guidance is cut to 6.5%-7.0% growth

Stryker shares fell about 10% to $279.98 before the open on Friday, after the medical device maker missed third-quarter estimates and cut its 2026 sales guidance. The stock was already down about 20% this year. Adjusted earnings per share were $3.52 against $3.55 expected. Revenue was $6.52 billion against $6.62 billion expected, up 7.6%. Stryker now expects 2026 organic sales growth of 6.5% to 7.0%, down from 8.3% to 9.3%. Its adjusted EPS guidance fell to $14.80 to $14.90 from $14.95 to $15.10. Chief executive officer Kevin Lobo said the Mako RPS hip and knee system is "off to a slow start." Spencer Stiles succeeds him and will issue the 2027 guidance early next year.

Yahoo Finance
Oct 29th, 2026
Stryker misses Q3 forecasts with $753M profit on $6.52B revenue

Stryker reported third-quarter profit of $753 million, or $1.96 per share, on Thursday. The Michigan-based medical device maker's adjusted earnings, which exclude asset impairment and amortisation costs, were $3.52 per share. Both results missed Wall Street forecasts. Analysts surveyed by Zacks Investment Research expected earnings of $3.56 per share and revenue of $6.58 billion; Stryker posted revenue of $6.52 billion. The company expects full-year earnings of $14.80 to $14.90 per share.

Associated Press
Oct 29th, 2026
Stryker Q3 sales rise 7.7% to $6.5B, but miss expectations; $3B added to buyback

Stryker reported third-quarter net sales of $6.5 billion, up 7.7% from a year earlier. Organic sales also rose 7.7%, driven mainly by higher unit volume. Reported net earnings fell 12.3% to $753 million, or $1.96 per diluted share, down 11.7%. Adjusted earnings per share rose 10.3% to $3.52, and adjusted operating margin rose 60 basis points to 26.2%. MedSurg and Neurotechnology sales grew 9.2% to $3.7 billion. Orthopaedics sales rose 5.7% to $2.9 billion. Chief executive officer Kevin A. Lobo said the results fell short of expectations, but he expects a solid fourth quarter. Stryker now expects 2026 organic sales growth of 6.5% to 7.0% and adjusted earnings per share of $14.80 to $14.90. It bought back $1.0 billion of stock in the quarter, and its board added $3.0 billion to the repurchase programme.

Yahoo Finance
Oct 28th, 2026
Stryker lags peers with 8.5% growth as plant problems, not hospitals, hit sales

Stryker's stock has lost 20.2% over the past 12 months, dividends included, while the S&P 500 returned 15.0%. Its revenue grew 8.5% over the latest four quarters, slower than four of its five peers, including Boston Scientific (13.5%) and Intuitive Surgical (20.5%). Management says hospital demand is steady. It blames the slowdown on a cybersecurity incident that halted manufacturing and on supply problems in peripheral vascular products. First-quarter fiscal 2026 revenue grew just 2.6%, and operating margin fell to 15.5%. Margin recovered to 25.2% in the second quarter. The stock fell 8.8% on September 8, 2026, after the chief financial officer said the vascular issue was unresolved. Third-quarter results are due October 29, 2026. Spencer Stiles will succeed Kevin Lobo as chief executive officer on January 1, 2027.